Relmada Therapeutics, Inc. RLMD Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s total liabilities & equity?
- Relmada Therapeutics, Inc. (RLMD) reported total liabilities & equity of $235.36M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s total liabilities & equity changed year-over-year?
- Relmada Therapeutics, Inc.'s total liabilities & equity increased by 750.3% year-over-year, from $27.68M to $235.36M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s total liabilities & equity?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s total liabilities & equity has grown at a -4.5% compound annual growth rate (CAGR), from $118.19M to $94M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.